We have applied subtype-selective antagonists of metabotropic glutamate (mGlu) receptors mGlu1 or mGlu5 [7-(hydroxyimino) cyclopropa [b]chromen-1a-carboxylate ethyl ester (CPCCOEt) or 2-methyl-6-(phenylethynyl)pyridine (MPEP)] to mixed rat cerebellar cultures containing both Purkinje and granule cells. The action of these two drugs on neuronal survival was cell specific. Although CPCCOEt (1, 10, 30 M) reduced the survival of Purkinje cells, MPEP (3 or 30 M) selectively reduced the survival of granule cells. Both effects required an early exposure of cultures to antagonists [from 3 to 6 d in vitro (DIV) for CPCCOEt, and from 3 to 6 or 6 to 9 DIV for MPEP]. Addition of MPEP from 6 to 9, 9 to 13, or 13 to 17 DIV also induced profound morphological changes in the dendritic tree and dendritic spines of Purkinje cells, suggesting that endogenous activation of mGlu5 receptors is required for the age-dependent refinement of Purkinje cell phenotype. In in vivo studies, an early blockade of mGlu1 receptors induced in rats by local injections of LY367385 (20 nmol/2 l), local injections of mGlu1 antisense oligonucleotides (12 nmol/2 l), or systemic administration of CPCCOEt (5 mg/kg, s.c.) from postnatal day (P) 3 to P9 reduced the number and dramatically altered the morphology of cerebellar Purkinje cells. In contrast, mGlu5 receptor blockade induced by local injections of antisense oligonucleotides reduced the number of granule cells but also produced substantial morphological changes in the dendritic tree of Purkinje cells. These results provide the first evidence that the development of cerebellar neurons is under the control of mGlu1 and mGlu5 receptors, i.e., the two mGlu receptor subtypes coupled to polyphosphoinositide hydrolysis.
Activation of glutamate receptors has been implicated in the regulation of differentiation and survival of developing CNS neurons. Most of the studies have focused on the role of NMDA receptors in the induction of neuronal phenotypes, promotion of neuronal survival, and synaptic remodeling during development (Balázs et al., 1988; Moran and Patel, 1989; Rabacchi et al., 1992; Burgoyne et al., 1993; Yuzaki et al., 1996; Marini et al., 1998) . However, metabotropic glutamate (mGlu) receptors have also been implicated in the regulation of developmental plasticity since the early times of their characterization (Nicoletti et al., 1986; Dudek and Bear, 1989) . mGlu receptors form a family of eight subtypes (named mGlu1 to mGlu8), of which mGlu1 and mGlu5 receptors, which form the first subgroup of subtypes, are coupled to polyphosphoinositide (PI) hydrolysis (Nakanishi, 1982; Pin and Duvoisin, 1995) . Glutamate-stimulated PI hydrolysis in brain slices shows a developmental peak in the early postnatal life and then progressively decreases with age (Nicoletti et al., 1986; Schoepp and Johnson, 1989) . This is paralleled by an early peak in the expression of mGlu5 receptors in most of the brain regions, including the cerebellum (Catania et al., 1994; Minakami et al., 1995; Romano et al., 1996; Casabona et al., 1997) . In the kitten visual cortex, the activity of mGlu receptors coupled to PI hydrolysis is greater between 3 and 5 weeks of postnatal life, a time that corresponds to the critical period of synaptic modification in response to monocular deprivation (Dudek and Bear, 1989) . A developmental pattern of expression of group-I mGlu receptors is also shown in cultured cerebellar granule cells, in which glutamate-stimulated PI hydrolysis peaks after 4 d in vitro (DIV) and declines at later stages of maturation (Aronica et al., 1993) . Interestingly, an early activation of mGlu5 receptors supports the survival of cultured granule cells (Copani et al., 1998) , raising the possibility that the age-dependent reduction in the expression of mGlu5 receptors contributes to the elimination of supranumerary granule cells in the intact cerebellum. Pharmacological activation of mGlu receptors combined with NGF application increases Purkinje cell survival in culture (Mount et al., 1993) , but which receptor subtype is involved and whether this effect is physiologically relevant are unknown. Purkinje cells are highly enriched in mGlu1 receptors (Aramori and Nakanishi, 1992; Görcs et al., 1993; Catania et al., 1994 ), but mGlu1 knock-out mice show no apparent changes in the number and only minor changes in the morphology of Purkinje cells (Aiba et al., 1994) . Similarly, the gross anatomy of the cerebellum is unchanged in mGlu5 knock-out mice (Lu et al., 1997) . Because compensatory changes might have occurred in knock-out mice, we decided to use novel subtype-selective mGlu1 or mGlu5 receptor antagonists or antisense oligonucleotides to examine how endogenous activation of these receptors affects the development of Purkinje cells.
MATERIALS AND METHODS Materials
7-(Hydroxy-imino) cyclopropa [b] chromen-1a-carboxylate ethyl ester (C PCC OEt), 2-methyl-6-(phenylethynyl)pyridine (M PEP), and (E)-2-methyl-6-styryl-pyridine (SI B-1893) were purchased from Tocris Cookson (Bristol, UK). 2-Methyl-4-carboxyphenyglycine (LY367385) and ␣-thioxanth-9-ylmethyl-4-carboxyphenylglycine (LY367366) were kind gifts from Dr. Ann K ingston (Eli Lilly, UK).
Mixed cerebellar cultures
Mixed cerebellar cultures were prepared from rats at postnatal day (P) 1, as described previously (Furuya et al., 1998) . C ells were plated at a final density of 5 ϫ 10 6 cells/ml in DM EM / F12 containing putrescine (100 M), sodium selenite (30 nM), progesterone (20 nM), bovine insulin (10 g /ml), transferrin (100 g /ml), tri-iodothyronine (T3) (0.5 ng /ml), bovine serum albumin (0.1 mg /ml), glutamine (3.9 mM), gentamicin (10 g /ml), and 1% FC S. The medium was partially replaced at 9 DIV with fresh serum-free DM EM / F12 containing the supplements and cytosine arabino-␤-f uranoside (4 M). C ell cultures were treated daily with M PEP and C PCC OEt dissolved in serum-free DM EM / F12. Three different types of treatment were performed: (1) in a first set of experiments, cultures were treated continuously with drugs from 4 to 13 DIV; (2) in a second set of experiments, cultures were treated only for 3 or 4 d at critical stages of Purkinje cell development. In particular, dishes were divided into four groups and treated from 3 to 5 DIV (and analyzed at 6 DIV); from 6 to 8 DIV (and analyzed at 9 DIV); from 9 to 12 DIV (and analyzed at 13 DIV); or from 13 to 16 DIV (and analyzed at 17 DIV). (3) In a third set of experiments, cultures were treated from 6 to 9 DIV with M PEP or C PCC OEt, extensively washed, and then analyzed at 14 DIV. Granule cell counting and morphological analysis of Purkinje cells were performed on the same dishes.
Animal treatment
Sprague Dawley newborn rats at P3 were injected through the scalp in the posterior region of the cerebellum (2-3 mm posterior to the lambda point) under conditions of deep hypothermia. The drugs LY367385 or LY367366 (both at doses of 20 nmol /2 l) were injected once every 2 d until P9. Animals were killed at P9 -10. In different animals we injected methylene blue to validate the site of injection. The region of injection was invariably located in the vermis in a region comprising the central lobe (lobules V I, V II, and V III), and the dye diff used anteriorly to anterodorsal lobe (lobules IV and V) and posteriorly to lobule I X as indicated in Altman and Bayer (1996) . "End-capped" antisense oligonucleotides (Oligo Therapeutics Inc.) directed against mGlu1 or mGlu5 mRNA were injected at doses of 12 nmol /2 l only at P3 and P5 (animals were killed at P9). The antisense sequences were as follows: T(s)C(s)AG-GCAGGCATCGGTTC(s)A(s)G, corresponding to the position 785-805 of mGlu1 sequence (GenBank accession number M61099) (Houamed et al., 1991) , and G(s)G(s)ATCAACAGAAGGACCA(s)T(s)T, corresponding to position 267-286 of mGlu5 sequence (GenBank accession number D10891) (Abe et al., 1992) . A scrambled mGlu5 oligonucleotide having the sequence G(s)G(s)AC TAAACAGGAGACAT(s)C(s)T was used as a control. C PCC OEt (5 mg / kg) was daily injected subcutaneously from P3 to P9.
Western blotting
Western blot analysis of mGlu5 receptors in rat hemicerebella was performed as described previously (Copani et al., 1998) .
Immunocytochemistry
Cultures. C ells were generally fixed with 4% paraformaldehyde/4% sucrose in Tris-buffered saline (TBS; 100 mM Tris, 0.9% NaC l) for 15 min. For mGlu1a staining, fixation with ice-cold methanol was preferred because it resulted in a more clearly defined signal than with paraformaldehyde. Permeabilization was performed in TBS with 0.1% Triton X-100 for 5 min. After blocking with 4% normal goat serum (NGS) for 30 min, incubation with primary antibodies was performed overnight at 4°C. A mouse monoclonal antibody against calbindin (1:1000; Swant, Bellinzona, Switzerland), rabbit polyclonal antibodies anti-glutamate decarboxylase (GAD)-67 (1:1000; Chemicon International, Temecula, CA), and rabbit polyclonal antibodies against mGlu1a (1:100; Chemicon International) and five (1:100; Upstate Biotechnology, Lake Placid, N Y) receptors were used. The following antigenic peptides (one-letter code), C PN V TYASV ILRDYKQSSSTL (corresponding to the C terminus of the mGlu1a receptors) and K SSPK DTLIIRDYTNSSSSL (corresponding to the C terminus of mGlu5a / b receptors), were used to test the specificity of immunolabeling. Both peptides were kindly provided by Dr R. Kuhn (Novartis Pharma, Basle, Switzerland). After three washes in TBS, biotin-conjugated goat anti-rabbit or anti-mouse secondary antibodies (1:200, Vector Laboratories, Burlingame, CA) were added for 1.5 hr. Immunostaining was revealed by the avidin -biotin -peroxidase method. In the mGlu5/calbindin double-labeling experiment, a dichlorotriazinyl amino fluorescein (DTAF)-conjugated goat anti-rabbit IgG (1:200; Jackson ImmunoResearch, West Grove, PA) and a C y3-conjugated goat anti-mouse IgG (1:200; Jackson ImmunoResearch) were used. In the mGlu5/GFAP double-labeling experiment, staining for mGlu5 was first developed using the DAB method; cultures were then fixed in paraformaldehyde for 10 min, blocked with 4% goat serum, and incubated again overnight with a rabbit anti-cow GFAP antibody (1:1000; Dako) that was revealed with a secondary DTAF-conjugated goat anti- Intact cerebellum. Brains were removed and fixed in 4% paraformaldehyde/ PBS for 2 d at 4°C and then cryoprotected in 30% sucrose for 3-7 d. Sagittal sections (20 m thick) were cut at the cryostate and serially attached to gelatin-coated slides. Slices were permeabilized for 30 min in TBS containing 0.2% Triton X-100. This was followed by a preincubation in TBS containing 4% NGS for 30 min. Sections were incubated overnight at 4°C in primary antibodies in TBS. Staining was developed as described above. Sections were rinsed in TBS, dehydrated in increasing concentrations of ethanol, clarified, and mounted on coverslips in a xylene-based mounting medium. Sections were also routinely Nissl stained for histological analysis.
Morphometric analysis
Images were analyzed by using the MCI D system (Imaging Research, St. C atharine's, Ontario) to evaluate the area, the total length of the dendritic tree, the number of branches, the diameter of primary dendrites, and the length of dendritic spines. Total length of the dendritic tree was calculated by adding the length of all branches of a single Purkinje cell. In the computation of spine length, no distinction was made between headed spines and filopodia-like processes, although it was clear that M PEP-treated cells bore a lower density of headed spines compared with control sister cultures. Granule cells present in a square of fixed area (1700 m 2 ; three determinations per slice) were counted in the internal granule layer of comparable sections at the level of preculminate fissure in the anterior cerebellum (lobules 3 and 4). The width of molecular layer was measured in the same region from both anti-calbindin and Nisslstained sections, and comparable results were obtained.
RESULTS

Endogenous activation of group-I mGlu receptors supports the maturation and survival of cerebellar Purkinje cells in culture
We used primary cultures of cerebellar neurons prepared from 1-d-old rats and grown in chemically defined medium with 1% serum. These cultures contained ϳ65-70% granule cells, 10% Purkinje cells, and 15-20% glial cells. Purkinje cells were identified by immunostaining with anti-calbindin antibodies (see below). Granule cells were identified by their characteristic morphology (small rounded cell bodies) associated with the absence of GAD-67 or GFAP immunoreactivity. Purkinje cells were viable for at least 21 d. The developmental profile of Purkinje cells in our cultures was identical to that described by Baptista et al. (1994) . At 3 DIV, calbindin-stained Purkinje cells showed rounded or fusiform cell bodies and multiple primary aspiny dendrites elongating from the whole cell surface (data not shown). At 6 DIV, most of the primary dendrites were retracted, and Purkinje cells showed a small dendritic tree (Fig. 1, CON -TROL) . The extension of the dendritic tree progressively increased between 9 and 17 DIV, as shown by the formation and elongation of secondary and tertiary branches (Fig. 1, CON -TROL) . Spines characterized by a globoid head and a thin neck were clearly visible on dendrites of cultured Purkinje cells after 6 DIV (see Fig. 4 A) . Under our experimental conditions, the number of Purkinje cells did not change substantially with age in culture, whereas granule cell number decreased by ϳ50% between 6 and 13 DIV (Fig. 3 A, B) .
We have performed immunocytochemical analysis to study the expression of mGlu1a and mGlu5 receptors in culture. mGlu1a receptor immunoreactivity was detected in both Purkinje and granule cells but not in glial cells. At 3 DIV, mGlu1a receptors showed low levels of expression in both neuronal types (data not shown) but were more heavily expressed in Purkinje cells than in granule cells at 6 DIV (Fig. 2 A) . At 9 -13 DIV, Purkinje cells were intensely labeled, and the receptor was apparently present in both the cell soma and dendrites (data not shown). In contrast, mGlu5 receptors were expressed in granule cells and astrocytes but not in Purkinje cells, as demonstrated by double labeling with anti-GFAP (Fig. 2 D, E) and anti-calbindin (Fig. 2 B, C) antibodies. The expression of mGlu5 receptors did not change between 3 and 9 DIV. No labeling was observed after preadsorbing mGlu1a and mGlu5 antibodies with 100 M of the respective antigenic peptide (data not shown).
To study how endogenous activation of mGlu1 and mGlu5 receptors affects the development of Purkinje cells, we have treated the cultures with CPCCOEt or MPEP, which behave as selective noncompetitive antagonists of mGlu1 and mGlu5 receptors, respectively (Annoura et al., 1996; Gasparini et al., 1999; Litschig et al., 1999) . In a first set of experiments, cell cultures were treated daily between 4 and 13 DIV and fixed at 14 DIV. Treatment with either drug dramatically altered the morphology of Purkinje cells. In the majority of treated Purkinje cells, the dendritic tree appeared poor and disorganized with short and thick dendrites, which were always devoid of tertiary branches. No major morphological feature could distinguish MPEP-and CPCCOEt-treated cells. However, MPEP-treated Purkinje cells showed less numerous (7.5 Ϯ 2 branches; n ϭ 15 cells) and slightly longer secondary branches than CPCCOEt-treated cells (15 Ϯ 2 branches; n ϭ 12 cells).
In other experiments, cultures were exposed to CPCCOEt or MPEP from 3 to 6, 6 to 9, 9 to 13, or 13 to 17 DIV. In each group, morphological analysis of Purkinje cells and cell counting were (n ϭ 11) (n ϭ 7) (n ϭ 10) (n ϭ 11) (n ϭ 7) (n ϭ 51) (n ϭ 50) (n ϭ 24) CPCCOEt 781 Ϯ 59* 2823 Ϯ 361 4408 Ϯ 238 33 Ϯ 1* 97 Ϯ 6 9 6Ϯ 4 7.16 Ϯ 0.2 5.61 Ϯ 0.2 5.654 Ϯ 0.1 (n ϭ 13) (n ϭ 13) (n ϭ 7) (n ϭ 13) (n ϭ 13) (n ϭ 7) (n ϭ 68) (n ϭ 37) (n ϭ 37)
Data represent mean Ϯ SEM. *p Ͻ 0.05 (one-way ANOVA ϩ Fisher's PLSD). n, Number of Purkinje cells analyzed. Cells were chosen randomly from three dishes, each from a different experiment.
performed at the end of the treatment. We adopted this strategy to examine how endogenous activation of mGlu1 and mGlu5 receptors regulates the maturation and survival of cerebellar neurons at particular time windows. An early blockade of mGlu1 receptor with CPCCOEt (30 M, from 3 to 6 DIV) substantially reduced the number of Purkinje cells (counted at 6 DIV) without changing the number of granule cells. CPCCOEt had no effect on Purkinje and granule cell survival at any later interval ranging from 6 to 17 DIV. Endogenous blockade of mGlu5 receptors with MPEP (30 M) did not affect the survival of Purkinje cells but reduced the number of granule cells when applied from 3 to 6 or from 6 to 9 DIV (Fig. 3 A, B) . This protocol of antagonist application was also useful for the study of how endogenous activation of mGlu1 or mGlu5 receptors affects the morphology of Purkinje cells (Fig. 1) . Purkinje cells exposed to CPCCOEt at early developmental stages (from 3 to 6 or 6 to 9 DIV) appeared smaller and bore short dendrites. This effect was visible with concentrations of 1, 10, and 30 M of CPCCOEt (the effect of 30 M is shown in Fig. 1 ). In contrast, MPEP had no effect when applied between 3 and 6 DIV but produced profound changes in Purkinje cell morphology at later developmental stages. In cultures exposed to MPEP (3 or 30 M) from 6 to 9 DIV, the majority of Purkinje cells exhibited longer, thinner, and less branched dendrites (Fig. 1 ). This aberrant developmental pattern was even more evident in cultures exposed to M PEP from 9 to 13 DIV, with Purkinje cell dendrites being longer and often devoid of secondary and tertiary branches (Fig. 1) . Morphometric analysis indicated that C PC -C OEt applied from 6 to 9 DIV significantly reduced the total length of the dendritic tree and the number of dendritic branches. M PEP affected all of these parameters when applied not only from 6 to 9 DIV but also from 9 to 13 DIV. In addition, the thickness of the primary dendrites of Purkinje cells was significantly reduced in cultures exposed to M PEP at any interval between 6 and 17 DIV ( Table 1 ). The typical morphological features of Purkinje cells treated from 6 to 9 DIV with M PEP were also observed after a 3 d treatment with SI B-1893 (30 M), which also behaves as a selective noncompetitive mGlu5 receptor antagonist (data not shown). The morphological changes of Purkinje cells observed at 9 DIV after a 3 d treatment with M PEP were also seen after 24 hr (i.e., between 8 and 9 DIV) but not after 0.5 or 3 hr of drug exposure (data not shown).
Besides producing a substantial effect on the gross morphology of Purkinje cells, a 3 d treatment with MPEP also influenced the morphogenesis of dendritic spines. Dendrites of Purkinje cells treated with MPEP from 6 to 9 DIV exhibited longer and thinner processes devoid of heads, which markedly differed from the headed mature spines of control cultures. (Fig. 4 A-C) . CPCCOEt applied from 6 to 9 DIV had no effect on the morphology of dendritic spines (Fig. 4C) .
To examine whether Purkinje cells are able to recover from a transient pharmacological blockade of mGlu1 or mGlu5 receptors, we have treated cultures with CPCCOEt or MPEP (both at 30 M) from 6 to 9 DIV as described previously, but then we have extensively washed the cultures (Fig. 5, legend) and allowed them to grow until 14 DIV. Although Purkinje cells in these cultures showed some morphological abnormalities, their dendrites were more developed than in cultures examined at the end of the 3 d exposure to CPCCOEt or MPEP, i.e., at 9 DIV, or at the end of a continuous exposure to CPCCOEt or MPEP from 6 to 14 DIV (Fig. 5) . This indicates that receptor blockade at a critical time window arrests or delays, but does not irreversibly impair, Purkinje cell maturation. 
Endogenous activation of mGlu1 and mGlu5 receptors supports the maturation and survival of cerebellar neurons in vivo
The compounds LY367385 and LY367366, which behave as competitive mGlu1 and mGlu1/5 antagonists, respectively (both at the dose of 20 nmol/2 l), as well as mGlu1 or mGlu5 antisense oligonucleotides (12 nmol/2 l) were injected into the cerebellar region, whereas the noncompetitive mGlu1 antagonist CPCOOEt was injected systemically (5 mg/kg, s.c.) in neonate rats (see Materials and Methods).
Pups at P9 -10 that had been treated with the mGlu1 receptor antagonist LY367385 showed a loss of Purkinje cells, which was remarkable in the vicinity of the injection site. Surviving Purkinje cells showed a shrunken cell body and a poorly developed dendritic tree, which appeared shorter and poorly branched (data not shown). A poorly developed dendritic tree of Purkinje cells was also observed in pups systemically treated with CPCCOEt ( Fig.  6 A, B) or locally injected with antisense oligonucleotides directed against mGlu1 receptors (Fig. 7C,F ) . Antisense treatment was effective in reducing mGlu1a expression in the Purkinje cell layer, as shown by immunohistochemical analysis (Fig. 7, compare A 
, B with D, E).
Pups injected with mGlu5 antisense oligonucleotides were used for the examination of how mGlu5 receptors affect cerebellar development. To select the animals in which antisense treatment was effective in reducing mGlu5 receptor expression, we performed Western blot analysis of hemicerebella (Fig. 8 A) . Four of five pups locally injected with antisense showed a clear-cut reduction in the expression of mGlu5 receptors, as compared with pups injected with a scrambled oligonucleotide (Fig. 8 A, SCR) . In the other hemicerebella of animals with a proven knockdown of mGlu5 receptors, we observed a reduction in cell number within the granule cell layer (Fig. 8 B, C) . Purkinje cells of these animals showed a stellate configuration resulting from the presence of short perisomatic dendrites emerging in all directions (Fig. 7I ) . There was no reduction in the expression of mGlu1a receptors in pups treated with mGlu5 antisense oligonucleotides (Fig. 7G,H ) .
A quantitative assessment of the width of the molecular layer and the number of granule cells after drug or antisense treatment is shown in Figure 9 , A and B, respectively. Note that (1) treatment with the mGlu1 receptor antagonist LY367385 reduced the width of the molecular layer but not the number of granule cells, (2) treatment with mGlu5 antisense oligonucleotides significantly reduced both the number of granule cells and the width of the molecular layer, and (3) a reduction in the cell number of the granular layer was also observed in pups treated with LY367366, a mixed mGlu1 and mGlu5 receptor antagonist (Fig. 9 A, B) . Purkinje cells of animals treated with LY376366 were smaller in size, and their dendrites were shorter and not polarized (data not shown).
DISCUSSION
The major finding of this paper is that endogenous activation of mGlu1 and mGlu5 receptors contributes to cerebellar development and that a selective blockade of these receptors within restricted time windows differentially affects the maturation of Purkinje cells. This discloses a major neurotrophic activity of group-I mGlu receptors during early postnatal development that did not emerge from the use of mGlu1 or mGlu5 knock-out mice (Aiba et al., 1994; Conquet et al., 1994; Lu et al., 1997) . Receptor blockade was achieved by using either antisense oligonucleotides or a battery of novel subtype-selective antagonists. CPCCOEt and MPEP (or SIB-1893) behave as potent and noncompetitive antagonists of mGlu1 and mGlu5 receptors, respectively (Annoura et al., 1996; Gasparini et al., 1999; Litschig et al., 1999) . LY367385 behaves as a competitive mGlu1 receptor antagonist, whereas LY367366 inhibits both mGlu1 and mGlu5 receptors with equal potency (Clark et al., 1997) . The latter two drugs are soluble and were preferred for intracerebral injections. Mixed cultures of cerebellar Purkinje and granule cells represent a suitable model to examine how endogenous activation of mGlu1 and mGlu5 receptors affects neuronal development. In these cultures, granule cells establish synaptic contacts with Purkinje cells as they do in the intact cerebellum and are known to use glutamate as a neurotransmitter. Hence, noncompetitive antagonists become optimal tools for the examination of how endogenous activation of mGlu1 or mGlu5 receptors affects cell maturation and survival. In culture, pharmacological inhibition of mGlu1 and mGlu5 receptors selectively impaired the survival of Purkinje and granule cells, respectively. Expression of mGlu1a receptors was higher in Purkinje than in granule cells, whereas mGlu5 receptors were expressed in granule cells but not in Purkinje cells. Although information on the expression of other mGlu1 splice variants is lacking, the use of antagonists allows us to conclude that a molecular cascade supporting cell survival is linked to mGlu1 receptors in Purkinje cells and to mGlu5 receptors in granule cells. This is consistent with previous findings showing that the developmental decline in the expression of mGlu5 receptors predisposes cultured granule cells to "low-K ϩ "-induced apoptosis (Copani et al., 1998) . Endogenous activation of mGlu1 receptors did not support granule cell survival, although these receptors are functionally coupled with ryanodine-sensitive intracellular Ca 2ϩ stores and L-type voltage-sensitive Ca 2ϩ channels in granule cells (Chavis et al., 1996) . Both mGlu1 and mGlu5 receptors are coupled to inositol phospholipid hydrolysis, but they differ in the kinetics of intracellular Ca 2ϩ response. Activation of recombinant mGlu1a receptors generates a single peaked increase in intracellular Ca 2ϩ , whereas activation of mGlu5 receptors produces Ca 2ϩ oscillations. The latter property is attributable to a particular threonine residue that is present only in mGlu5 receptors and is phosphorylated by protein kinase C (Kawabata et al., 1996) . An attractive hypothesis is that oscillatory increases in intracellular Ca 2ϩ are needed for granule cell viability but are not required for Purkinje cell survival. The use of receptor antagonists in cerebellar cultures revealed that mGlu1 or mGlu5 receptors control cell survival within a restricted time window during early stages of neuronal development. This correlates nicely with evidence that the expression of mGlu5 receptors in granule cells decreases with age (Catania et al., 1994; Copani et al., 1998) and that mGlu1-mediated responses in cultured Purkinje cells peak at 4 DIV and decline thereafter (Yuzaki and Mikoshiba, 1992) .
Interestingly, selective blockade of mGlu5 receptors produced substantial morphological changes in Purkinje cells, including changes in the shape of dendritic spines that are consistent with a delay in their maturation (Zif and Smith, 1996; Jontes and Smith, 2000) . Because Purkinje cells lack mGlu5 receptors, it is conceivable that MPEP acts primarily on granule cells, which are known to influence Purkinje cell differentiation and survival by releasing glutamate and/or neurotrophins (Baptista et al., 1994; Morrison and Mason, 1998; Hirai and Launey, 2000) . Changes in Purkinje cell morphology were particularly evident after 9 DIV and therefore could not be ascribed to the reduction in granule cell number induced by MPEP. However, mGlu5 receptor blockade might have reduced the spontaneous activity of granule cells, thus limiting the major synaptic input to Purkinje cells. Alternatively, inhibition of mGlu5 receptors present in astrocytes might have disrupted a trophic mechanism based on a glial-Purkinje cell interaction. The effects produced by a transient inhibition of mGlu1 or mGlu5 receptors on dendritic growth of Purkinje cells were substantial but not irreversible, as indicated by the partial recovery of the dendritic tree after washing out CPCCOEt or MPEP.
Systemic injections of CPCCOEt and local infusions with LY367385 or mGlu1 antisense oligonucleotides produced morphological abnormalities in the neonate rat cerebellum, which are indicative of an arrest or delay in the maturation of Purkinje cells. These abnormalities (cell shrinkage and dystrophic neurites) are reminiscent of those seen in culture treated with CPCCOEt and strongly suggest that activation of mGlu1 receptors is required for the early development of Purkinje cells. We did not use MPEP for in vivo studies because high concentrations of MPEP (Ͼ100 M) may interact with NMDA receptors , and we could not exclude the possibility that such concentrations could be reached in the cerebellum after systemic or local injec- tions. For this reason, we used antisense oligonucleotides to examine whether mGlu5 receptors have any role in cerebellar development. Antisense-induced knockdown of mGlu5 receptor was associated with a reduction in granule cell number and alterations in the polarity and arborization of Purkinje cell dendrites, similar to what we observed in cultures treated with MPEP.
In conclusion, we have shown that endogenous activation of mGlu1 and mGlu5 receptors is necessary for a proper development of cerebellar Purkinje cells, with the two receptors operating at different times and on different cells. mGlu1 receptor blockade impaired Purkinje cell development only at early stages of maturation, when dendritic remodeling is presumably independent of innervation by granule cell axons (Armengol and Sotelo, 1991) . Interestingly, the expression and subcellular distribution of mGlu1a receptors in Purkinje cells is also independent of synaptic inputs (Takács et al., 1997) . Resident astrocytes are a possible source for the glutamate-activating mGlu1 receptors at these early stages of development. Our scenario is clearly different from that reported in mGlu1 knock-out mice, where the only relevant morphological alteration (i.e., the persistence of multiple climbing fiber synapses on Purkinje cells) depends on processes that occur late in development (Kano et al., 1997) . mGlu5 receptors might be activated primarily on granule cells or astrocytes and then influence the phenotype of Purkinje cells indirectly, through a synaptic or a paracrine mechanism. These results raise the possibility that changes in the activity of mGlu1 or mGlu5 receptors occurring at critical times of development may contribute to the pathophysiology of cerebellar disorders.
